MCID: ADL017
MIFTS: 63

Adult T-Cell Leukemia

Categories: Rare diseases, Cancer diseases, Immune diseases, Skin diseases, Blood diseases

Aliases & Classifications for Adult T-Cell Leukemia

MalaCards integrated aliases for Adult T-Cell Leukemia:

Name: Adult T-Cell Leukemia 37 12 36 14
Adult T-Cell Leukemia/lymphoma 12 49 55
Atll 49 55
Adult T-Cell Leukaemia/lymphoma 49
Leukemia-Lymphoma, Adult T-Cell 41
T Cell Leukemia Lymphoma Adult 51
Adult T-Cell Lymphoma/leukemia 69
Adult T-Cell Leukaemia 49
Adult T-Cell Lymphoma 49
Leukemia, T-Cell 69

Characteristics:

Orphanet epidemiological data:

55
adult t-cell leukemia/lymphoma
Inheritance: Multigenic/multifactorial,Not applicable; Age of onset: Adult;

Classifications:



External Ids:

Disease Ontology 12 DOID:0050523
ICD10 32 C91.5 C91.50
MeSH 41 D015459
NCIt 46 C3184
Orphanet 55 ORPHA86875
MESH via Orphanet 42 D015459
UMLS via Orphanet 70 C0023493
ICD10 via Orphanet 33 C91.5
KEGG 36 H00009
UMLS 69 C0023493

Summaries for Adult T-Cell Leukemia

NIH Rare Diseases : 49 Adult T-cell leukemia/lymphoma (ATL) is is a rare and aggressive T-cell lymphoma that is linked to infection by the human T-cell lymphotropic virus 1 (HTLV-1). The exact mechanism by which HTLV-I infection causes the ATL is unknown. The clinical features of ATL include generalized swelling of the lymph nodes (lymphadenopathy), increased liver and spleen size (hepatosplenomegaly), immunosuppression, high levels of calcium in the blood, lytic bone lesions (spots that appear as “holes” on a standard bone x-ray), and skin lesions.  There are four basic clinical variants of ATL: acute (60% of cases), lymphomatous (20 % of cases), chronic (10% of cases) and smoldering (10% of cases). The best treatment for these patients is unclear and patients should be enrolled in clinical trials whenever possible. Medication may include CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine and prednisone) or EPOCH (etoposide, vincristine, doxorubicin, cyclophosphamide and prednisone). In some patients, a bone marrow transplant may be recommended. Last updated: 9/13/2016

MalaCards based summary : Adult T-Cell Leukemia, also known as adult t-cell leukemia/lymphoma, is related to tropical spastic paraparesis and t-cell leukemia. An important gene associated with Adult T-Cell Leukemia is PMAIP1 (Phorbol-12-Myristate-13-Acetate-Induced Protein 1), and among its related pathways/superpathways are HTLV-I infection and Viral carcinogenesis. The drugs Cyclophosphamide and Epirubicin have been mentioned in the context of this disorder. Affiliated tissues include t cells, bone and bone marrow, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Disease Ontology : 12 A T-cell leukemia that results_in abnormal increase of lymphocytes, derives from T-cells, has material basis in Human T-lymphotropic virus 1, which is transmitted_by sexual contact, transmitted_by contaminated needles used by intravenous-drug users, and transmitted_by breast feeding. The infection results_in_formation_of skin lesions.

Related Diseases for Adult T-Cell Leukemia

Diseases in the T-Cell Leukemia family:

Adult T-Cell Leukemia Acute T Cell Leukemia
Human T-Cell Leukemia Virus Type 1 Human T-Cell Leukemia Virus Type 2
Human T-Cell Leukemia Virus Type 3 Leukemia, B-Cell, Chronic
Leukemia, T-Cell, Chronic

Diseases related to Adult T-Cell Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 163)
# Related Disease Score Top Affiliating Genes
1 tropical spastic paraparesis 32.4 CNTN2 FOXP3 IL2 IL2RA
2 t-cell leukemia 31.2 CD7 CNTN2 IL2 IL2RA JUND PMAIP1
3 cutaneous t cell lymphoma 30.5 IL2 IL2RA TNFRSF8
4 mycosis fungoides 30.4 CD7 IL2 IL2RA TNFRSF8
5 cervicitis 30.2 CDKN2A IL2 IL2RA
6 combined immunodeficiency, x-linked 30.1 BCL11B IL2 IL2RA
7 acute lymphocytic leukemia 29.9 CDKN2A IL2 TP53
8 sezary's disease 29.8 CD7 IL2 IL2RA TNFRSF8
9 lymphopenia 29.7 FAS FOXP3 IL2 IL2RA
10 leukemia, acute myeloid 29.7 BCL2L1 CD7 CDKN2A IL2 TP53
11 b-cell lymphomas 29.6 BCL2L1 CCND2 CDKN2A TNFRSF8 TP53
12 human t-cell leukemia virus type 1 11.5
13 myelopathy, htlv-1-associated 11.4
14 precursor t-cell acute lymphoblastic leukemia 11.3
15 leukemia 11.2
16 retrovirus-associated myelopathy 11.1
17 lymphoma 11.1
18 brain stem astrocytic neoplasm 10.5 CDKN2A TP53
19 squamous cell carcinoma of the oropharynx 10.5 CDKN2A TP53
20 hematopoietic stem cell transplantation 10.5
21 acute t cell leukemia 10.4
22 pityriasis lichenoides et varioliformis acuta 10.4 CD7 TNFRSF8
23 spitz nevus 10.4 CDKN2A TP53
24 pityriasis lichenoides 10.4 CD7 TNFRSF8
25 central nervous system lymphoma 10.4 CDKN2A IL2 TP53
26 ocular cancer 10.3 CDKN2A IL2 TP53
27 acquired immunodeficiency syndrome 10.3 IL2 IL2RA TP53
28 pancreas adenocarcinoma 10.3 CDKN2A FOXP3 TP53
29 lymphoma, hodgkin, classic 10.3 IL2 IL2RA TNFRSF8
30 hypercalcemia, infantile, 1 10.3
31 spastic paraparesis 10.3
32 spasticity 10.3
33 caplan's syndrome 10.3 FAS FOXP3
34 keratinizing squamous cell carcinoma 10.3 CDKN2A TP53
35 retinal cancer 10.3 CCND2 CDKN2A TP53
36 sensory system cancer 10.3 CCND2 CDKN2A TP53
37 marek disease 10.3 TNFRSF8 TP53
38 colon lymphoma 10.3 CD7 CDKN2A TNFRSF8
39 cell type cancer 10.2 CDKN2A IL2 TP53
40 squamous cell carcinoma of the larynx 10.2 CDKN2A TP53
41 ovarian cancer 1 10.2 BCL2L1 IL2 TP53
42 pneumonia 10.2
43 gastrointestinal system cancer 10.1 BCL2L1 CDKN2A TP53
44 peripheral t-cell lymphoma 10.1
45 scabies 10.1
46 blood group, i system 10.1
47 graft-versus-host disease 10.1
48 hepatitis 10.1
49 dermatitis 10.1
50 endotheliitis 10.1

Graphical network of the top 20 diseases related to Adult T-Cell Leukemia:



Diseases related to Adult T-Cell Leukemia

Symptoms & Phenotypes for Adult T-Cell Leukemia

GenomeRNAi Phenotypes related to Adult T-Cell Leukemia according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.83 JUND TP53 BCL2L1 CDKN2A EPC1 FAS
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.83 JUND TP53 BCL2L1 CDKN2A EPC1 FAS

MGI Mouse Phenotypes related to Adult T-Cell Leukemia:

43 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.37 TNFRSF8 TP53 PRDM16 PTHLH CCND2 BCL11B
2 hematopoietic system MP:0005397 10.36 TNFRSF8 TP53 PRDM16 PTHLH EPC1 CCND2
3 behavior/neurological MP:0005386 10.35 JUND TP53 PTHLH CNTN2 CCND2 BCL11B
4 immune system MP:0005387 10.31 JUND TNFRSF8 TP53 PRDM16 PTHLH EPC1
5 cellular MP:0005384 10.3 PTHLH JUND PRDM16 TP53 TXN CADM1
6 growth/size/body region MP:0005378 10.29 PTHLH JUND PRDM16 TP53 BCL11B BCL2L1
7 homeostasis/metabolism MP:0005376 10.25 PTHLH JUND PRDM16 TP53 CCND2 BCL11B
8 digestive/alimentary MP:0005381 10.11 PTHLH PRDM16 TP53 CDKN2A FOXP3 IL2
9 mortality/aging MP:0010768 10.1 PTHLH JUND PRDM16 TP53 TXN CCND2
10 integument MP:0010771 9.97 PTHLH PRDM16 TP53 BCL11B BCL2L1 CDKN2A
11 liver/biliary system MP:0005370 9.92 JUND PRDM16 TP53 CCND2 CDKN2A FOXP3
12 reproductive system MP:0005389 9.85 PTHLH JUND TP53 CADM1 CCND2 BCL2L1
13 respiratory system MP:0005388 9.61 JUND PRDM16 TP53 PTHLH CDKN2A IL2
14 vision/eye MP:0005391 9.32 TP53 PRDM16 PTHLH CCND2 BCL11B CDKN2A

Drugs & Therapeutics for Adult T-Cell Leukemia

Drugs for Adult T-Cell Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 427)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
2
Epirubicin Approved Phase 4,Phase 2 56420-45-2 41867
3
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 33419-42-0 36462
4
Gemcitabine Approved Phase 4,Phase 2,Phase 1 95058-81-4 60750
5
Ifosfamide Approved Phase 4,Phase 3,Phase 2,Phase 1 3778-73-2 3690
6
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 53-03-2 5865
7
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 2068-78-2, 57-22-7 5978
8
Daclizumab Approved, Investigational Phase 4,Phase 1,Phase 2 152923-56-3
9
Cisplatin Approved Phase 4,Phase 2,Phase 1 15663-27-1 2767 441203 84093
10
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-02-2 5743
11
Bupivacaine Approved, Investigational Phase 4,Phase 1,Phase 2 38396-39-3, 2180-92-9 2474
12
Ropivacaine Approved Phase 4 84057-95-4 175805 71273
13 Antibodies Phase 4,Phase 3,Phase 1,Phase 2
14 Immunoglobulins Phase 4,Phase 3,Phase 1,Phase 2
15 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
16 Anesthetics Phase 4,Phase 3,Phase 1,Phase 2
17 Central Nervous System Depressants Phase 4,Phase 3,Phase 1,Phase 2
18 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
19 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
20 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
21 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
22 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
23 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
24 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1
25 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
26 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
27 Etoposide phosphate Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
28 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1
29 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
30 Hormones Phase 4,Phase 3,Phase 2,Phase 1
31 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
32 Isophosphamide mustard Phase 4,Phase 3,Phase 2,Phase 1 0
33 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
34 BB 1101 Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
35 Dexamethasone acetate Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 1177-87-3
36 Anesthetics, Local Phase 4,Phase 1,Phase 2
37 Calamus Nutraceutical Phase 4
38
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
39
Amoxicillin Approved, Vet_approved Phase 3 26787-78-0 33613 2171
40
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1 2764
41
Cefepime Approved, Investigational Phase 3 88040-23-7 5479537
42
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
43
Ofloxacin Approved Phase 3 82419-36-1 4583
44
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 23214-92-8 31703
45
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1 135968-09-1
46
rituximab Approved Phase 3,Phase 2,Phase 1,Early Phase 1 174722-31-7 10201696
47
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Early Phase 1 22916-47-8 4189
48
Cytarabine Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 147-94-4 6253
49
Fludarabine Approved Phase 3,Phase 2,Phase 1 21679-14-1, 75607-67-9 30751
50
Methotrexate Approved Phase 3,Phase 2,Phase 1,Early Phase 1 1959-05-2, 59-05-2 126941

Interventional clinical trials:

(show top 50) (show all 365)

# Name Status NCT ID Phase Drugs
1 Pilot Study of Combination Therapy With CHOP-Zenapax (CHOP-daclizumab) Completed NCT01418430 Phase 4 CHOP-daclizumab
2 Neurotoxicity of Spinal Anesthesia With Ropivacaine and Bupivacaine Recruiting NCT03293472 Phase 4 Ropivacaine;Bupivacaine
3 CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL Recruiting NCT02533700 Phase 4 CEOP/IVE/GDP chemotherapy regimen;CEOP chemotherapy regimen for 6 cycles
4 MP Diagnostics HTLV Blot 2.4 Post-Market Clinical Study Active, not recruiting NCT03226119 Phase 4
5 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
6 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
7 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
8 Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma Unknown status NCT00052936 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
9 A Study for Aggressive Adult T-cell Leukemia-lymphoma (ATLL) Completed NCT00145002 Phase 3 VCAP-AMP-VECP with G-CSF and intrathecal prophylaxis;biweekly-CHOP with G-CSF and intrathecal prophylaxis
10 Treatment of Acute Lymphoblastic Leukemia (ALL) in Younger Adults Completed NCT00327678 Phase 3 Rituximab;Imatinib Mesylate
11 Study of Treatment High Risk and/or Low Risk Acute Lymphoblastic leukémia(ALL) Adults Stage III Completed NCT00483132 Phase 3 interferon alpha 2a
12 ALL2008 Protocol for Childhood Acute Lymphoblastic Leukemia (ALL) - 6MP Consolidation Therapy Completed NCT00816049 Phase 3 6MPindividualized;6MPfixed
13 Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Who Have Undergone Stem Cell Transplantation Completed NCT00031668 Phase 3
14 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
15 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
16 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
17 Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
18 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
19 St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer Completed NCT00005805 Phase 3
20 Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count Completed NCT00003805 Phase 3 piperacillin sodium;piperacillin-tazobactam;tazobactam sodium;vancomycin
21 Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter Completed NCT00006083 Phase 3 Fragmin
22 Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer Completed NCT00070382 Phase 3 darbepoetin alfa;epoetin alfa
23 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
24 Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma Completed NCT00005590 Phase 3 levofloxacin
25 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
26 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
27 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3 ondansetron
28 Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment Recruiting NCT02881086 Phase 3 Rituximab;Nelarabine;PEG-Asparaginase;Imatinib;Idarubicin;Dexamethasone;Cyclophosphamide;Fludarabine;Vincristine;Mercaptopurine;VP16;Daunorubicin (DNR);Methotrexate;Cytarabine;Vindesine;Adriamycin;Prednisolone
29 Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma Recruiting NCT03117751 Phase 2, Phase 3 Prednisone;Vincristine;Daunorubicin;Pegaspargase;Erwinase®;Rituximab;Cyclophosphamide;Cytarabine;Mercaptopurine;Dasatinib;Methotrexate;Blinatumomab;Ruxolitinib;Bortezomib;Dexamethasone;Doxorubicin;Etoposide;Clofarabine;Vorinostat;Idarubicin
30 Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents Recruiting NCT03020030 Phase 3 Pegaspargase;Erwinia asparaginase;Cyclophosphamide;CYTARABINE;DASATINIB;DEXAMETHASONE;Dexrazoxane;Doxorubicin;ETOPOSIDE;HYDROCORTISONE;LEUCOVORIN CALCIUM;MERCAPTOPURINE;METHOTREXATE;NELARABINE;Vincristine
31 International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia Active, not recruiting NCT01117441 Phase 3 PEG-L-asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;doxorubicin hydrochloride;etoposide;ifosfamide;mercaptopurine;methotrexate;prednisone;thioguanine;vincristine sulfate;vindesine;daunoxome;fludarabine
32 Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma Active, not recruiting NCT00408005 Phase 3 Asparaginase;Cyclophosphamide;Cytarabine;Daunorubicin Hydrochloride;Dexamethasone;Doxorubicin Hydrochloride;Leucovorin Calcium;Mercaptopurine;Methotrexate;Nelarabine;Pegaspargase;Prednisone;Thioguanine;Vincristine Sulfate
33 Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer Active, not recruiting NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
34 Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma Suspended NCT02112916 Phase 3 Bortezomib;Cyclophosphamide;Cytarabine;Daunorubicin Hydrochloride;Dexamethasone;Doxorubicin Hydrochloride;Etoposide;Hydrocortisone Sodium Succinate;Ifosfamide;Leucovorin Calcium;Mercaptopurine;Methotrexate;Pegaspargase;Thioguanine;Vincristine Sulfate
35 Combination Chemotherapy With or Without Etoposide in Treating Older Patients With Non-Hodgkin's Lymphoma Terminated NCT00060385 Phase 2, Phase 3 CHOP regimen;EPOCH regimen;cyclophosphamide;doxorubicin hydrochloride;etoposide;prednisone;vincristine sulfate
36 High-Dose Chemotherapy Given Together With Peripheral Blood Stem Cell Transplant in Treating Patients With Intestinal T-Cell Lymphoma Unknown status NCT00669812 Phase 2 carmustine;cyclophosphamide;cytarabine;doxorubicin hydrochloride;epirubicin hydrochloride;etoposide;ifosfamide;melphalan;methotrexate;prednisolone;vincristine sulfate
37 Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas Unknown status NCT01805037 Phase 1, Phase 2 brentuximab vedotin
38 Combination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic Disorders Unknown status NCT00008307 Phase 2 cyclosporine;fludarabine phosphate;melphalan;methylprednisolone;mycophenolate mofetil
39 Alemtuzumab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV T-Cell Non-Hodgkin's Lymphoma Unknown status NCT00363090 Phase 1, Phase 2 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
40 Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma Unknown status NCT00621036 Phase 2 methotrexate;thiotepa
41 Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disorders Unknown status NCT00740467 Phase 2 busulfan;cyclophosphamide;cyclosporine;fludarabine phosphate;mycophenolate mofetil
42 Arsenic Trioxide in Treating Patients With Recurrent or Refractory Acute Leukemia, Chronic Myeloide Leukemia, Myelodysplasia, Lymphoma, or Myeloma Unknown status NCT00003885 Phase 2 arsenic trioxide
43 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
44 Lenalidomide in HTLV-1 Adult T-Cell Leukemia Completed NCT01274533 Phase 2 Lenalidomide
45 Phase II Study of KW-0761 in Subjects With CCR4-positive Adult T-cell Leukemia-lymphoma Completed NCT00920790 Phase 2
46 Campath-1H for Treating Adult T-Cell Leukemia/Lymphoma Completed NCT00061048 Phase 2
47 A Phase II Study Of Imtox-25 In Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma Completed NCT01378871 Phase 2 IMTOX-25
48 Phase II Study of the Efficacy and Toxicity of Ontak(Registered Trademark) (Denileukin Diftitox) in the Therapy of Adult T-Cell Leukemia Completed NCT00117845 Phase 2
49 506U78 In Relapsed Or Refractory Acute Lymphoblastic Leukemia (T-ALL) Completed NCT00684619 Phase 2 Nelarabine
50 Multicenter, Randomized, Open-label, Parallel-group Study to Compare mLSG15 + KW-0761 to mLSG15 Completed NCT01173887 Phase 2 VCAP/AMP/VECP(mLSG15)

Search NIH Clinical Center for Adult T-Cell Leukemia

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Adult T-Cell Leukemia cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Adult T-Cell Leukemia:
Hematopoietic stem cells for treatment of hematologic malignancies
Embryonic/Adult Cultured Cells Related to Adult T-Cell Leukemia:
Bone marrow-derived hematopoietic stem cells

Cochrane evidence based reviews: leukemia-lymphoma, adult t-cell

Genetic Tests for Adult T-Cell Leukemia

Anatomical Context for Adult T-Cell Leukemia

MalaCards organs/tissues related to Adult T-Cell Leukemia:

38
T Cells, Bone, Bone Marrow, Skin, Liver, Thyroid, Breast

Publications for Adult T-Cell Leukemia

Articles related to Adult T-Cell Leukemia:

(show top 50) (show all 889)
# Title Authors Year
1
Indolent, waxing and waning cutaneous presentation of HTLV-1-associated adult T-cell leukemia/lymphoma in an HIV-1-positive patient. ( 29094771 )
2018
2
A Review of New Findings in Adult T-cell Leukemia-Lymphoma: A Focus on Current and Emerging Treatment Strategies. ( 29411267 )
2018
3
Adult T-cell leukemia/lymphoma can be indistinguishable from other more common T-cell lymphomas. The University of Miami experience with a large cohort of cases. ( 29449683 )
2018
4
Successful treatment of post-transplant relapsed adult T cell leukemia after cord blood transplantation with low-dose, short-term lenalidomide. ( 29382244 )
2018
5
Adult T cell leukemia/lymphoma with different pathological features in each tumor site. ( 29427186 )
2018
6
Expression pattern of immunosurveillance-related antigen in adult T-cell leukemia/lymphoma. ( 29297942 )
2018
7
Outcomes of patients with relapsed aggressive adult T-cell leukemia-lymphoma: clinical effectiveness of anti-CCR4 antibody and allogeneic hematopoietic stem cell transplantation. ( 29371324 )
2018
8
Role of up-front allogeneic hematopoietic stem cell transplantation for patients with aggressive adult T-cell leukemia-lymphoma: a decision analysis. ( 29371687 )
2018
9
Adult T-Cell Leukemia/Lymphoma With Primary Lacrimal Gland Involvement. ( 29068833 )
2018
10
Syngeneic hematopoietic stem cell transplantation from HTLV-1 seropositive twin for adult T-cell leukemia-lymphoma. ( 29358601 )
2018
11
Retraction notice to Inhibition of proliferation and induction of apoptosis by 2-benzoyl-3-phenyl-6,7-dichloroquinoxaline 1,4-dioxide in adult T-cell leukemia cells. ( 29273235 )
2018
12
Deep sequencing of the T cell receptor visualizes reconstitution of T cell immunity in mogamulizumab-treated adult T cell leukemia. ( 29399406 )
2018
13
Prognostic relevance of integrated genetic profiling in adult T-cell leukemia/lymphoma. ( 29084771 )
2018
14
Dual inhibition of the mTORC1 and mTORC2 signaling pathways is a promising therapeutic target for adult T-cell leukemia. ( 29077243 )
2018
15
Development of sugar chain-binding single chain variable fragment antibody to adult T-cell leukemia cells using glyco-nanotechnology and phage display method. ( 29351623 )
2018
16
Acute myelitis resembling human T-lymphotropic virus type 1-associated myelopathy presenting as high-signal-intensity long cord lesions on T2-weighted magnetic resonance images combined with lymphoma-type adult T-cell leukemia/lymphoma. ( 27817856 )
2017
17
Adult T cell leukemia aggressivenness correlates with loss of both 5-hydroxymethylcytosine and TET2 expression. ( 28881727 )
2017
18
Expression and significance of Pim-3 kinase in adult T-cell leukemia. ( 28833639 )
2017
19
Galectin-9 as a Predictive Marker for the Onset of Immune-Related Adverse Effects Associated with Anti-CCR4 MoAb Therapy in Patients with Adult T Cell Leukemia. ( 28321034 )
2017
20
Genetic alterations in adult T-cell leukemia/lymphoma. ( 28627735 )
2017
21
Mogamulizumab for the treatment of relapsed or refractory adult T-cell leukemia-lymphoma. ( 28756726 )
2017
22
Crucial role of carbonic anhydrase IX in tumorigenicity of xenotransplanted adult T-cell leukemia-derived cells. ( 28075522 )
2017
23
Welder's pulmonary hemosiderosis associated with systemic iron overload following exacerbation of acute adult T-cell leukemia/lymphoma. ( 28883221 )
2017
24
Generalized rash and lymphocytosis as clinical onset adult T-cell leukemia/lymphoma. ( 28645687 )
2017
25
Detection of human T-cell lymphotropic virus type I-specific cytotoxic T-cells may predict treatment responses in adult T-cell leukemia/lymphoma patients. ( 28656327 )
2017
26
Cyclin-dependent kinase 9 is a novel specific molecular target in adult T-cell leukemia/lymphoma. ( 28646117 )
2017
27
Unilateral conjunctival infiltration of Adult T-cell leukemia/lymphoma. Case report and literature review. ( 29279551 )
2017
28
Development of a complete human IgG monoclonal antibody to transferrin receptor 1 targeted for adult T-cell leukemia/lymphoma. ( 28189691 )
2017
29
Epidemiological and clinical features of adult T-cell leukemia-lymphoma in Japan, 2010-2011: A nationwide survey. ( 28905463 )
2017
30
Evaluation of INOS, ICAM-1, and VCAM-1 gene expression: A study of adult T cell leukemia malignancy associated with HTLV-1. ( 28110427 )
2017
31
Monitoring molecular response in adult T-cell leukemia by high-throughput sequencing analysis of HTLV-1 clonality. ( 28811663 )
2017
32
Mogamulizumab for relapsed adult T-cell leukemia-lymphoma: Updated follow-up analysis of phase I and II studies. ( 28776876 )
2017
33
Adult T-cell leukemia cell-induced uveitis: rapid increase in adult T-cell leukemia cells disrupts the blood-ocular barrier. ( 28677112 )
2017
34
Early Onset of HTLV-1 Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP) and Adult T-cell Leukemia/Lymphoma (ATL): Systematic Search and Review. ( 28582585 )
2017
35
Risk Assessment in Adult T Cell Leukemia/Lymphoma Treated with Allogeneic Hematopoietic Stem Cell Transplantation. ( 29155320 )
2017
36
A Unique T-Cell Receptor Amino Acid Sequence Selected by Human T-Cell Lymphotropic Virus Type 1 Tax301-309-Specific Cytotoxic T Cells in HLA-A24:02-Positive Asymptomatic Carriers and Adult T-Cell Leukemia/Lymphoma Patients. ( 28724766 )
2017
37
Long-term clinical remission maintained after cessation of zidovudine and interferon-I+ therapy in chronic adult T-cell leukemia/lymphoma. ( 29090417 )
2017
38
Hematopoeitic stem cell transplantation for adult T cell leukemia-lymphoma: Who is the best candidate? ( 27786571 )
2017
39
Altered Expression of Cell Cycle Regulators in Adult T-Cell Leukemia/ Lymphoma Patients. ( 29090234 )
2017
40
Adult T-Cell Leukemia/Lymphoma. ( 28796966 )
2017
41
Dismal outcome of allogeneic hematopoietic stem cell transplantation for relapsed adult T-cell leukemia/lymphoma, a Japanese nation-wide study. ( 28067877 )
2017
42
Anti-laminin-332-type mucous membrane pemphigoid in a patient with adult T-cell leukemia/lymphoma and graft-versus-host disease. ( 28771781 )
2017
43
Hypersensitivity reaction to I^-lactam antibiotics in patients with adult T-cell leukemia/lymphoma treated with mogamulizumaba8c. ( 28793956 )
2017
44
Choices and Challenges in the Treatment of Adult T-Cell Leukemia/Lymphoma. ( 28796965 )
2017
45
Human T-Cell Leukemia Virus Type 1 Infection and Adult T-Cell Leukemia. ( 29052136 )
2017
46
Human T-cell leukemia virus type I Tax genotype analysis in Okinawa, the southernmost and remotest islands of Japan: Different distributions compared with mainland Japan and the potential value for the prognosis of aggressive adult T-cell leukemia/lymphoma. ( 28866351 )
2017
47
Clonality of HTLV-1-infected T cells as a risk indicator for development and progression of adult T-cell leukemia. ( 29296760 )
2017
48
Therapy-related Acute Myeloid Leukemia after the Long-term Administration of Low-dose Etoposide for Chronic-type Adult T-cell Leukemia-lymphoma: A Case Report and Literature Review. ( 28717086 )
2017
49
Detection of Tax-specific CTLs in lymph nodes of adult T-cell leukemia/lymphoma patients and its association with Foxp3 positivity of regulatory T-cell function. ( 28599462 )
2017
50
C-MYC and Its Main Ubiquitin Ligase, FBXW7, Influence Cell Proliferation and Prognosis in Adult T-cell Leukemia/Lymphoma. ( 28498285 )
2017

Variations for Adult T-Cell Leukemia

Expression for Adult T-Cell Leukemia

Search GEO for disease gene expression data for Adult T-Cell Leukemia.

Pathways for Adult T-Cell Leukemia

Pathways related to Adult T-Cell Leukemia according to KEGG:

36
# Name Kegg Source Accession
1 HTLV-I infection hsa05166
2 Viral carcinogenesis hsa05203

Pathways related to Adult T-Cell Leukemia according to GeneCards Suite gene sharing:

(show all 30)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.69 BCL2L1 CCND2 CDKN2A FAS IL2 IL2RA
2
Show member pathways
12.87 BCL2L1 CCND2 FAS IL2 IL2RA TP53
3
Show member pathways
12.74 BCL2L1 CDKN2A FAS PMAIP1 TP53
4
Show member pathways
12.72 CCND2 FAS IL2 IL2RA TP53
5 12.65 BCL2L1 CCND2 CDKN2A FAS IL2 IL2RA
6 12.43 BCL11B FAS FOXP3 IL2 IL2RA TNFRSF8
7
Show member pathways
12.37 BCL2L1 IL2 IL2RA TP53
8 12.32 BCL2L1 CCND2 CDKN2A IL2 IL2RA TP53
9
Show member pathways
12.27 CCND2 CDKN2A FAS PMAIP1 TP53
10
Show member pathways
12.26 BCL2L1 CCND2 IL2 IL2RA
11 12.2 CCND2 CDKN2A PMAIP1 TP53
12 12.16 BCL11B BCL2L1 CCND2 TP53
13 12.15 BCL2L1 FAS PMAIP1 TXN
14 11.89 CCND2 CDKN2A PMAIP1 TP53
15
Show member pathways
11.73 BCL2L1 FAS PMAIP1
16 11.71 CCND2 PMAIP1 TP53
17 11.7 CD7 IL2 IL2RA
18
Show member pathways
11.67 FOXP3 IL2 IL2RA
19 11.66 BCL2L1 JUND TP53 TXN
20 11.55 BCL2L1 CCND2 CDKN2A FAS PMAIP1 TP53
21 11.52 BCL2L1 CDKN2A FAS PMAIP1 TP53
22 11.4 FOXP3 IL2 IL2RA
23
Show member pathways
11.38 BCL2L1 CCND2 FOXP3 IL2 IL2RA
24 11.37 FAS JUND TP53
25
Show member pathways
11.34 BCL2L1 FAS PMAIP1
26 11.28 BCL2L1 PMAIP1 TP53
27
Show member pathways
11.26 FAS FOXP3 IL2 IL2RA
28
Show member pathways
11.01 CDKN2A PMAIP1 TP53
29 10.73 BCL2L1 CDKN2A FAS IL2 TP53
30 10.72 BCL2L1 TP53

GO Terms for Adult T-Cell Leukemia

Biological processes related to Adult T-Cell Leukemia according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.97 CD7 FAS IL2 IL2RA TNFRSF8
2 negative regulation of apoptotic process GO:0043066 9.95 BCL11B BCL2L1 CCND2 FAS IL2 TP53
3 apoptotic process GO:0006915 9.87 BCL2L1 CADM1 CDKN2A FAS IL2RA PMAIP1
4 negative regulation of cell proliferation GO:0008285 9.85 BCL11B CDKN2A FOXP3 PTHLH TNFRSF8 TP53
5 negative regulation of inflammatory response GO:0050728 9.77 FOXP3 IL2 IL2RA
6 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.74 CDKN2A FAS PMAIP1
7 positive regulation of apoptotic process GO:0043065 9.73 BCL2L1 CDKN2A FAS PMAIP1 TNFRSF8 TP53
8 response to cytokine GO:0034097 9.7 BCL2L1 JUND TP53
9 response to radiation GO:0009314 9.67 BCL2L1 JUND TXN
10 positive regulation of intrinsic apoptotic signaling pathway GO:2001244 9.63 BCL2L1 PMAIP1 TP53
11 positive regulation of protein oligomerization GO:0032461 9.61 PMAIP1 TP53
12 negative regulation of immune response GO:0050777 9.61 FOXP3 IL2RA
13 replicative senescence GO:0090399 9.58 CDKN2A TP53
14 T cell homeostasis GO:0043029 9.58 FOXP3 IL2RA PMAIP1
15 positive regulation of regulatory T cell differentiation GO:0045591 9.56 FOXP3 IL2
16 negative regulation of T-helper 17 cell differentiation GO:2000320 9.51 FOXP3 IL2
17 regulation of T cell homeostatic proliferation GO:0046013 9.43 IL2 IL2RA
18 regulation of regulatory T cell differentiation GO:0045589 9.33 FOXP3 IL2 IL2RA
19 regulation of mitochondrial membrane permeability GO:0046902 9.13 BCL2L1 PMAIP1 TP53
20 negative regulation of lymphocyte proliferation GO:0050672 8.8 FOXP3 IL2 IL2RA
21 positive regulation of transcription by RNA polymerase II GO:0045944 10.08 BCL11B CDKN2A EPC1 FOXP3 IL2 JUND
22 negative regulation of transcription by RNA polymerase II GO:0000122 10.02 EPC1 FOXP3 JUND PRDM16 TP53 TXN
23 negative regulation of transcription, DNA-templated GO:0045892 10 CDKN2A EPC1 FOXP3 PRDM16 TP53

Sources for Adult T-Cell Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....